Skip to main content
. Author manuscript; available in PMC: 2011 Oct 1.
Published in final edited form as: J Surg Res. 2010 Mar 12;163(2):276–281. doi: 10.1016/j.jss.2010.02.021

Figure 1.

Figure 1

A) Effect of A-779024 treatment on cell death in MIA-PaCa-2 cells at 24 and 48 hours of therapy over a broad dose-range, with effect of caspase inhibition by ZVad-fmk co-treatment at 48 hrs (5 µM A-779024 treatment), and B) effect of A-779024 treatment on caspase 3 cleavage in MIA-PaCa-2 cells at 24 and 48 hours, with effect of caspase inhibition by ZVad-fmk co-treatment. Paclitaxel is used as a positive control for caspase 3 cleavage.